183 related articles for article (PubMed ID: 25986064)
21. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer.
Sinn BV; von Minckwitz G; Denkert C; Eidtmann H; Darb-Esfahani S; Tesch H; Kronenwett R; Hoffmann G; Belau A; Thommsen C; Holzhausen HJ; Grasshoff ST; Baumann K; Mehta K; Dietel M; Loibl S
Ann Oncol; 2013 Sep; 24(9):2316-24. PubMed ID: 23661292
[TBL] [Abstract][Full Text] [Related]
22. Immunoreactivity of monoclonal antibody BW835 represents a marker of progression and prognosis in early gastric cancer.
Baldus SE; Zirbes TK; Glossmann J; Fromm S; Hanisch FG; Mönig SP; Schröder W; Schneider PM; Flucke U; Karsten U; Thiele J; Hölscher AH; Dienes HP
Oncology; 2001; 61(2):147-55. PubMed ID: 11528254
[TBL] [Abstract][Full Text] [Related]
23. The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer.
Duncan TJ; Watson NF; Al-Attar AH; Scholefield JH; Durrant LG
World J Surg Oncol; 2007 Mar; 5():31. PubMed ID: 17349047
[TBL] [Abstract][Full Text] [Related]
24. Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer.
Croce MV; Isla-Larrain MT; Rua CE; Rabassa ME; Gendler SJ; Segal-Eiras A
J Histochem Cytochem; 2003 Jun; 51(6):781-8. PubMed ID: 12754289
[TBL] [Abstract][Full Text] [Related]
25. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
[TBL] [Abstract][Full Text] [Related]
26. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.
Ochsenreither S; Fiedler WM; Conte GD; Macchini M; Matos I; Habel B; Ahrens-Fath I; Raspagliesi F; Lorusso D; Keilholz U; Rolling C; Kebenko M; Klinghammer KF; Saavedra O; Baumeister H; Zurlo A; Garralda E
ESMO Open; 2022 Apr; 7(2):100447. PubMed ID: 35397434
[TBL] [Abstract][Full Text] [Related]
27. Expression of mucin 1 possessing a 3'-sulfated core1 in recurrent and metastatic breast cancer.
Ideo H; Hinoda Y; Sakai K; Hoshi I; Yamamoto S; Oka M; Maeda K; Maeda N; Hazama S; Amano J; Yamashita K
Int J Cancer; 2015 Oct; 137(7):1652-60. PubMed ID: 25787775
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of mucin expression profiles in breast carcinoma with signet ring cells: a clinicopathological study.
Ohashi R; Hayama A; Yanagihara K; Yamashita K; Sakatani T; Takei H; Naito Z
Diagn Pathol; 2016 Nov; 11(1):131. PubMed ID: 27846863
[TBL] [Abstract][Full Text] [Related]
29. EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.
Czogalla B; Kuhn C; Heublein S; Schmöckel E; Mayr D; Kolben T; Trillsch F; Burges A; Mahner S; Jeschke U; Hester A
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2519-2527. PubMed ID: 31485769
[TBL] [Abstract][Full Text] [Related]
30. Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.
Tang Y; Wang L; Zhang P; Wei H; Gao R; Liu X; Yu Y; Wang L
Clin Vaccine Immunol; 2010 Dec; 17(12):1903-8. PubMed ID: 20876819
[TBL] [Abstract][Full Text] [Related]
31. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21.
Adluri S; Gilewski T; Zhang S; Ramnath V; Ragupathi G; Livingston P
Br J Cancer; 1999 Apr; 79(11-12):1806-12. PubMed ID: 10206297
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical characterization of a panel of 56 antibodies with normal human small intestine, colon, and breast tissues.
Cao Y; Karsten U; Hilgers J
Tumour Biol; 1998; 19 Suppl 1():88-99. PubMed ID: 9422093
[TBL] [Abstract][Full Text] [Related]
33. Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer.
Tang Y; Cui X; Xiao H; Qi S; Hu X; Yu Q; Shi G; Zhang X; Gu J; Yu Y; Wang L; Li Y
Mol Med Rep; 2017 May; 15(5):2659-2664. PubMed ID: 28447743
[TBL] [Abstract][Full Text] [Related]
34. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
35. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
Grinstead JS; Schuman JT; Campbell AP
Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
[TBL] [Abstract][Full Text] [Related]
36. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes.
Kontani K; Taguchi O; Narita T; Izawa M; Hiraiwa N; Zenita K; Takeuchi T; Murai H; Miura S; Kannagi R
Br J Cancer; 2001 May; 84(9):1258-64. PubMed ID: 11336479
[TBL] [Abstract][Full Text] [Related]
37. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S
Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207
[TBL] [Abstract][Full Text] [Related]
38. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
[TBL] [Abstract][Full Text] [Related]
39. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.
Pegram MD; Borges VF; Ibrahim N; Fuloria J; Shapiro C; Perez S; Wang K; Schaedli Stark F; Courtenay Luck N
Breast Cancer Res; 2009; 11(5):R73. PubMed ID: 19811637
[TBL] [Abstract][Full Text] [Related]
40. Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients.
Utsunomiya T; Yonezawa S; Sakamoto H; Kitamura H; Hokita S; Aiko T; Tanaka S; Irimura T; Kim YS; Sato E
Clin Cancer Res; 1998 Nov; 4(11):2605-14. PubMed ID: 9829723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
